Completed PHASE2 INTERVENTIONAL 1-arm NCT00815919

Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease

A Phase II Trial of Bortezomib (Velcade) Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease

Sponsor: Dana-Farber Cancer Institute

Conditions Chronic Graft Versus Host Disease

Updated 6 times since 2017 Last updated: Jun 29, 2015 Started: Dec 31, 2008 Primary completion: Jan 31, 2012 Completion: Jan 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Chronic Graft Versus Host Disease and is currently completed. Dana-Farber Cancer Institute leads this study, which shows 6 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dana-Farber Cancer Institute
Millennium Pharmaceuticals, Inc.

Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States